Regional Management Corp. (RM)
NYSE: RM · Real-Time Price · USD
37.63
+0.32 (0.86%)
Aug 13, 2025, 9:38 AM - Market open
Checkpoint Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Checkpoint Therapeutics stock have an average target of 30, which predicts a -20.28% decrease from the current stock price of 37.63.
Price Target: $30 (-20.28%)
Analyst Consensus: Hold
* Price targets were last updated on May 2, 2025.
Analyst Ratings
The average analyst rating for Checkpoint Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Keefe, Bruyette & Woods | Keefe, Bruyette & Woods | Hold Maintains $33 → $30 | Hold | Maintains | $33 → $30 | -20.28% | May 2, 2025 |
| Stephens & Co. | Stephens & Co. | Hold Initiates $30 | Hold | Initiates | $30 | -20.28% | Nov 13, 2024 |
| Keefe, Bruyette & Woods | Keefe, Bruyette & Woods | Hold Maintains $28 → $33 | Hold | Maintains | $28 → $33 | -12.30% | Aug 1, 2024 |
| BTIG | BTIG | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Jun 7, 2024 |
| Keefe, Bruyette & Woods | Keefe, Bruyette & Woods | Hold Maintains $26 → $28 | Hold | Maintains | $26 → $28 | -25.59% | May 3, 2024 |
Financial Forecast
Revenue This Year
644.20M
from 569.59M
Increased by 13.10%
Revenue Next Year
704.42M
from 644.20M
Increased by 9.35%
EPS This Year
4.50
from 4.14
Increased by 8.60%
EPS Next Year
6.73
from 4.50
Increased by 49.60%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 676.3M | 738.2M | 685.6M |
| Avg | 644.2M | 704.4M | 672.5M |
| Low | 548.5M | 598.6M | 639.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 18.7% | 14.6% | -2.7% |
| Avg | 13.1% | 9.3% | -4.5% |
| Low | -3.7% | -7.1% | -9.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 4.77 | 9.21 | 12.35 |
| Avg | 4.50 | 6.73 | 12.11 |
| Low | 4.15 | 5.60 | 11.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 15.1% | 104.8% | 83.6% |
| Avg | 8.6% | 49.6% | 80.1% |
| Low | 0.1% | 24.5% | 71.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.